Hutchmed China Ltd ADR Down 2.92% To $14.29 After Earnings

Hutchmed China Ltd ADR (HCM) said before open Monday that it earned $0.97 per share in FALSE 2023. The company reported $532.9 million in revenue

In the same quarter a year ago, the company lost $0.96 per share on revenue of $202 million.

The stock is down 2.92% to $14.29 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

Wall Street Analysts had an average rating of Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Hutchmed China Ltd ADR has performed a little below average during the past few months. Before the report, Hutchmed China Ltd ADR received a Long-Term Technical Rank by InvestorsObserver of 36, putting it in the bottom half of stocks. The firm set a 52-week high on January 26, 2023 at $21.28 and set a 52-week low on October 24, 2022 at $7.39.

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.